| MeSH term | MeSH ID | Detail |
|---|---|---|
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hernia, Hiatal | D006551 | 3 associated lipids |
| HIV Seropositivity | D006679 | 15 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Hyperemesis Gravidarum | D006939 | 2 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Hypoproteinemia | D007019 | 1 associated lipids |
| Immunoproliferative Small Intestinal Disease | D007161 | 2 associated lipids |
| Infant, Premature, Diseases | D007235 | 7 associated lipids |
| Influenza, Human | D007251 | 11 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Çekin AH et al. | Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. | 2017 | Turk J Gastroenterol | pmid:28007678 |
| Yamamoto S et al. | Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. | 2017 | Biochem. Biophys. Res. Commun. | pmid:27998764 |
| Panozzo C et al. | Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. | 2017 | Biochim. Biophys. Acta | pmid:28888990 |
| Santos MA et al. | Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. | 2017 | Am. J. Med. | pmid:27984010 |
| Smibert OC et al. | Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. | 2017 | AIDS Res. Hum. Retroviruses | pmid:28791872 |
| Hiroi S et al. | Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. | 2017 | BMJ Open | pmid:28760790 |
| Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
| Takemoto Y et al. | Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. | 2017 | Intern. Med. | pmid:28717096 |
| Alba C et al. | Antibiotic resistance in Helicobacter pylori. | 2017 | Curr. Opin. Infect. Dis. | pmid:28704226 |
| Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
| Sun W et al. | Synergistic drug combination effectively blocks Ebola virus infection. | 2017 | Antiviral Res. | pmid:27890675 |
| Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
| Hung IFN et al. | Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. | 2017 | Chest | pmid:27884765 |
| Ustundag GH et al. | The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. | 2017 | Can J Gastroenterol Hepatol | pmid:28656129 |
| Peng X et al. | Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. | 2017 | Int J Med Sci | pmid:28638276 |
| Ozturk O et al. | Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. | 2017 | Arab J Gastroenterol | pmid:28601610 |
| Aguilera-Correa JJ et al. | Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. | 2017 | Diagn. Microbiol. Infect. Dis. | pmid:27863951 |
| Alirezaei A et al. | Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. | 2017 | Iran J Kidney Dis | pmid:28575885 |
| Katayama Y et al. | Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. | 2017 | Life Sci. | pmid:27825902 |
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Moj D et al. | Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. | 2017 | AAPS J | pmid:27822600 |
| Angol DC et al. | from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. | 2017 | Biomed Res Int | pmid:28555193 |
| Akpinar Z et al. | Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. | 2017 | Arab J Gastroenterol | pmid:28532623 |
| Beckman E et al. | A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. | 2017 | J. Clin. Microbiol. | pmid:28515219 |
| Stieler Stewart AL et al. | Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. | 2017 | Equine Vet. J. | pmid:28238211 |
| Bichler EK et al. | Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. | 2017 | J. Neurophysiol. | pmid:27733592 |
| Tsugawa K et al. | Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. | 2017 | Clin. Exp. Nephrol. | pmid:27614743 |
| Ivanová L et al. | Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. | 2017 | Environ. Res. | pmid:28183039 |
| Varma MV et al. | Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. | 2017 | Clin. Pharmacol. Ther. | pmid:27648490 |
| Huet D et al. | [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. | 2017 | Rev Mal Respir | pmid:27639948 |
| El Haj C et al. | The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? | 2017 | Med. Microbiol. Immunol. | pmid:27639707 |
| Jia L et al. | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28711353 |
| Seyama S et al. | Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). | 2017 | J. Antimicrob. Chemother. | pmid:27999037 |
| Zerbetto De Palma G et al. | Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. | 2017 | Microb. Drug Resist. | pmid:27391421 |
| Okuda M et al. | Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. | 2017 | Pediatr Int | pmid:27223686 |
| Bewick J et al. | The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. | 2017 | Clin Otolaryngol | pmid:27223120 |
| Legendre T et al. | [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. | 2017 | Encephale | pmid:27178256 |
| Choi HS et al. | Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. | 2017 | Jpn. J. Infect. Dis. | pmid:27169951 |
| Serrano CA et al. | Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. | 2017 | J. Pediatr. Gastroenterol. Nutr. | pmid:27159208 |
| Yatera K et al. | The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. | 2017 | Respir Investig | pmid:29153420 |
| Laidler N | Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. | 2017 | BMJ Case Rep | pmid:29275384 |
| Chang KH et al. | Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. | 2017 | J. Matern. Fetal. Neonatal. Med. | pmid:27687157 |
| Abadi ATB | Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. | 2017 | World J. Gastroenterol. | pmid:29085187 |
| Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
| Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
| Chen MJ et al. | Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. | 2017 | J. Antimicrob. Chemother. | pmid:28961996 |
| Kim SY et al. | Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. | 2017 | Helicobacter | pmid:28940815 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Tsay FW et al. | A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. | 2017 | Antimicrob. Agents Chemother. | pmid:28807915 |
| Manniello MD et al. | Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility. | 2017 | Int J Pharm | pmid:28377314 |
| Van der Paardt AL et al. | Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. | 2017 | Eur. Respir. J. | pmid:28331034 |
| Souto Filho JTD et al. | Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. | 2017 | Ann. Hematol. | pmid:28315923 |
| Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
| Koratala A et al. | Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. | 2017 | Blood Purif. | pmid:28268216 |
| Lin CM et al. | Is ionizing radiation a risk factor to diffuse panbronchiolitis? | 2017 | QJM | pmid:28069906 |
| Chew KL et al. | Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. | 2017 | J. Med. Microbiol. | pmid:28874233 |
| Miura S et al. | [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. | 2017 | Gan To Kagaku Ryoho | pmid:28860442 |
| McCallum GB et al. | Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. | 2017 | Cochrane Database Syst Rev | pmid:28828759 |
| de Ãvila BE et al. | Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. | 2017 | Nat Commun | pmid:28814725 |
| Zhang D et al. | Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. | 2017 | Medicine (Baltimore) | pmid:28796053 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Makihara K et al. | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 | Cancer Chemother. Pharmacol. | pmid:28711984 |
| Tanabe H et al. | Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. | 2017 | Dig. Dis. Sci. | pmid:28664410 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Sue S et al. | The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. | 2017 | Intern. Med. | pmid:28566587 |
| Hu Y et al. | Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. | 2017 | Front Cell Infect Microbiol | pmid:28529929 |
| Jeong SH et al. | Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. | 2017 | Int. J. Infect. Dis. | pmid:28522316 |
| Ufuk A et al. | In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. | 2017 | Mol. Pharm. | pmid:28252969 |
| Iwayama K et al. | Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. | 2017 | BMC Pharmacol Toxicol | pmid:28235416 |
| Komiya K et al. | Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. | 2017 | Respir. Res. | pmid:28219384 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
| Su J et al. | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. | 2017 | Medicine (Baltimore) | pmid:28207505 |
| Branquinho D et al. | Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? | 2017 | BMC Gastroenterol | pmid:28202013 |
| Inukai K et al. | Effect of gel formation on the dissolution behavior of clarithromycin tablets. | 2017 | Int J Pharm | pmid:28196716 |
| Miftahussurur M et al. | Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28193745 |
| Zhang Z et al. | In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Int. J. Antimicrob. Agents | pmid:28188830 |
| Kristin F et al. | Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. | 2017 | Eur J Pharm Sci | pmid:28179133 |
| Chen D et al. | Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. | 2017 | Antimicrob. Agents Chemother. | pmid:28167563 |
| Fan W et al. | An unusual case of folliculitis spinulosa decalvans. | 2016 | Cutis | pmid:27814407 |
| Miftahussurur M et al. | Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. | 2016 | BMC Microbiol. | pmid:27809767 |
| Phaw NA and Tsai HH | Eosinophilic gastroenteritis: a challenge to diagnose and treat. | 2016 | BMJ Case Rep | pmid:27613263 |
| Plate A | [Not Available]. | 2016 | Praxis (Bern 1994) | pmid:27606919 |
| Huh CW et al. | Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. | 2016 | PLoS ONE | pmid:27588679 |
| Khonche A et al. | Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. | 2016 | Drug Res (Stuttg) | pmid:27351245 |
| Büchsel M et al. | A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. | 2016 | Diagn. Microbiol. Infect. Dis. | pmid:27342785 |
| Lin LC et al. | Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. | 2016 | World J. Gastroenterol. | pmid:27340362 |
| Wong AY et al. | Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. | 2016 | JAMA Intern Med | pmid:27136661 |
| Zollner-Schwetz I et al. | Primary resistance of Helicobacter pylori is still low in Southern Austria. | 2016 | Int. J. Med. Microbiol. | pmid:27134190 |
| Georgopoulos SD et al. | Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. | 2016 | Eur. J. Intern. Med. | pmid:27134145 |
| Blake Z | Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. | 2016 | BMJ | pmid:26955978 |
| Seyama S et al. | Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. | 2016 | Antimicrob. Agents Chemother. | pmid:26953210 |
| Ji Z et al. | The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. | 2016 | Medicine (Baltimore) | pmid:26937912 |
| Kefeli A et al. | Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. | 2016 | Bosn J Basic Med Sci | pmid:26773183 |
| Iyer G and Alexander GC | Cardiovascular risks associated with clarithromycin. | 2016 | BMJ | pmid:26769796 |
| Wong AY et al. | Cardiovascular outcomes associated with use of clarithromycin: population based study. | 2016 | BMJ | pmid:26768836 |
| Djennane-Hadibi F et al. | High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. | 2016 | Microb. Drug Resist. | pmid:26554340 |
| Siddiqui TR et al. | Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. | 2016 | J Pak Med Assoc | pmid:27339574 |
| Apostolopoulos P et al. | Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. | 2016 | Scand. J. Gastroenterol. | pmid:26435055 |